Lesley.SeymourMD

Medical Oncologist, Professor of Oncology Queens University, Director Investigational New Drug Program, Canadian Clinical Trials Group.

[IND Program CCTG @INDProgramCCTG]

@CDNCancerTrials Wonderful to have Carol join us in early clinical trials research

[Lesley.SeymourMD @LSeymourMD]

Wonderful news and very well deserved @CDNCancerTrials

[IND Program CCTG @INDProgramCCTG]

Lillian L. Siu, MD, FAACR, Elected as American Association for Cancer Research President-Elect for 2024-2025 | AACR | News Releases https://t.co/BLtPljoxaj

[Lesley.SeymourMD @LSeymourMD]

Congratulations Joe - it’s been an enormous privilege to have (and continue to) work with you - your contributions to cancer research nationally and globally cannot be overstated

[CCTG @CDNCancerTrials]

Dr. Joseph Pater #CCTG's founding director recognized for a lifetime of work in cancer research with his appointment as an Officer of the Order of Canada - his clinical research has improved the lives of Canadians with cancer. #OrderOfCanada #GGHonours 
https://t.co/QvTq1Fs6gm

[Elisabeth de Vries @VriesElisabeth]

New feature ESMO-MCBS scorecards: visualization of the score. When interested, please give your feedback. @myESMO @curzua_28 @rsnfehrmann https://t.co/xs2tsepH3Z

[IND Program CCTG @INDProgramCCTG]

Pembro Plus Platinum-Based Chemotherapy Improves Survival in Advanced Pleural Mesothelioma https://t.co/LPLzDlnIVk

[IND Program CCTG @INDProgramCCTG]

Dr Quincy Chu concluding his presentation of IND.227, a collaboration of
@istitutotumori
@IFCTlung
@CDNCancerTrials

[Lesley.SeymourMD @LSeymourMD]

@IFCTlung @INDProgramCCTG Then and now!

[Lesley.SeymourMD @LSeymourMD]

#ASCO18 @CDNCancerTrials @IFCTlung Great meeting with CCTG and IFCT today planning IND227 - first line mesothelioma trial with pembrolizumab

[CCTG @CDNCancerTrials]

#ASCO23 is this weekend stop by and see @ALLIANCE_org NCCTG N0147 (#CCTG CRC2): Artificial intelligence–derived immune phenotypes for prediction of prognosis in patients with stage III colon cancer

Poster Session 3542: https://t.co/ZPNiwsDpdM

[CCTG @CDNCancerTrials]

If you are attending #ASCO23 make sure to visit this poster presentation - #CCTG CO26: Reversion of RAS mutations in metastatic colorectal cancer in the CCTG CO26 clinical trial.

Poster Session 3567: https://t.co/afnhj9xxum
#SolvingCancerTogether

[Annie Ellis @Stigetta]

Marie Plante: Int’l P3 trial radical hysterectomy & pelvic node dissection (RH) vs simple hysterectomy & pelvic node dissection (SH) in pts w/low-risk early-stage cervical ca (LRESC):  Gyn Cancer Intergroup study led by Canadian Cancer Trials Grp (CCTG CX.5-SHAPE) #ASCO23 #gyncsm

[Dr Riyaz Shah @DrRiyazShah]

#mesothelioma

[GBOT Alerta @GBOT_Alerta]

🧐IND.227: fase III randomizado comparando CIS/PEM X CIS/PEM/PEMBRO. N=440 ⬆️OS HR: 0,79. >>Impacto histologia ñ-epitelioide e > EORTC prognostic risk, contudo mediana numericamente inferior ao CK743. ↔️PFS ↔️TRO #ASCO23

[Marcelo Corassa, MD. @MarceloCorassa]

IND.227: PhIII, Platinum + Pem + Pembro x Platinum + Pem in mesothelioma. mOS 17.28 x 16.13 months, HR 0.79, p 0.0324. Pronounced benefit in patients with non-epithelial subtypes. #ASCO23 #LCSM @GBOT_Alerta

[Ritrattodellasalute @ritrattosalute]

Novità per il trattamento del #mesotelioma dai risultati dello studio IND.227, presentati ad @ASCO. L’articolo: https://t.co/ttpPR6n4PK

#ascodailynews #ASCO23 #specialeASCO23

[Chul Kim @chulkimMD]

IND.227: cisplatin/pemetrexed/pembrolizumab vs. chemo alone in pleural mesothelioma by Dr. Chu.

OS (primary endpoint): 17.28 vs. 16.13 mo (HR 0.79, statistically sig).

ORR: 61% vs. 38% (!), also favoring the combo

Chemo-IO is a promising approach in mesothelioma

[Sanjay Popat @DrSanjayPopat]

Great to see IND.227: long awaited. Chemo-pbro vs chemo. Mostly epithel subtyp. 61% CPS+ OS improved HR0.79, 16 to17mo median; PFS benefit. CPS not predictive.
Great work @CDNCancerTrials

Will the addition of beva improve this? Let’s see… #ASCO23 @etop_ibcsg

[Jordi Remon @JordiRemon]

IO+Chemo work in all thoracic 🫁 malignancies including pleural mesothelioma: IND227 trial. Results mirror CheckMate 743. Today the dilemma in 1st L: IO+IO vs IO+CT?
We need predictive mrk for choosing 1st L or decide based on histology subtype:IO+IO non-epithelioid? #ASCO2023